.png){kind=icon}
返回
Large-vessel vasculitis
.png){kind=icon}
OA
AI
DOI：10.1038/s41572-021-00327-5.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches and is the most common primary vasculitis in adults. LVV comprises two distinct conditions, giant cell arteritis and Takayasu arteritis, although the phenotypic spectrum of primary LVV is complex. Non-specific symptoms often predominate and so patients with LVV present to a range of health-care providers and settings. Rapid diagnosis, specialist referral and early treatment are key to good patient outcomes. Unfortunately, disease relapse remains common and chronic vascular complications are a source of considerable morbidity. Although accurate monitoring of disease activity is challenging, progress in vascular imaging techniques and the measurement of laboratory biomarkers may facilitate better matching of treatment intensity with disease activity. Further, advances in our understanding of disease pathophysiology have paved the way for novel biologic treatments that target important mediators of disease in both giant cell arteritis and Takayasu arteritis. This work has highlighted the substantial heterogeneity present within LVV and the importance of an individualized therapeutic approach. Future work will focus on understanding the mechanisms of persisting vascular inflammation, which will inform the development of increasingly sophisticated imaging technologies. Together, these will enable better disease prognostication, limit treatment-associated adverse effects, and facilitate targeted development and use of novel therapies. Large-vessel vasculitis is the most common primary vasculitis in adults, manifesting as inflammation of the aorta and its major branches. This Primer reviews the epidemiology, pathophysiology, diagnosis and management of this disease, highlights its effects on patient quality of life, and discusses future research questions.
Keyword:
GIANT-CELL ARTERITIS
PLACEBO-CONTROLLED TRIAL
QUALITY-OF-LIFE
SEVERE ISCHEMIC COMPLICATIONS
ENDOTHELIAL GROWTH-FACTOR
POPULATION-BASED COHORT
DOUBLE-BLIND TRIAL
TERM-FOLLOW-UP
TAKAYASU-ARTERITIS
POLYMYALGIA-RHEUMATICA
期刊
N
IF:
60.6
论文数:
652
被引数:
3.8W
机构
查看更多机构
引用论文
18F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.png)
ARTHRITIS & RHEUMATOLOGY
OAAI
ARTHRITIS & RHEUMATOLOGYIF10.9
OAAI分享收藏分享收藏 查看更多内容